Immutep IMMP
NASDAQ IMMP
$3.56 +0.10 (+2.89%)
As of: Nov 11, 2026 · 3:59 PM EST

Immutep (IMMP) Current Deferred Revenue (2025)

Updated

Immutep (IMMP) reported Current Deferred Revenue of $16.96 million for the quarter ended Dec 31, 2025.

Analysis

Immutep (IMMP) Current Deferred Revenue (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Immutep 252.65 Mn 41.62 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 17.30 Mn
API Access

Immutep Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=IMMP&period=max&api_key=YOUR_API_KEY